.jpeg)
{{ variable.name }}
Lazatinib is an important first-line treatment option for EGFR mutation-positive non-small cell lung cancer (NSCLC), and is especially suitable for patients with brain metastases or who require enhanced therapeutic efficacy.
1. Generic name: Lazertinib (Lazertinib)
2. Trade name: LAZCLUZE™.
It is suitable for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21L858R substitution mutation confirmed by FDA-approved testing.
80mg tablet , 240mg tablet
1. Active ingredient: lazertinib mesylate.
2. Excipients: Including croscarmellose sodium, magnesium stearate, mannitol, etc., and the coating contains glyceryl monocaprylate, iron oxide pigment, etc.
1. Recommended dose of : 240 mg orally once a day, combined with Amivantamab, before or after a meal. Swallow tablet whole without crushing or chewing.
2. Treatment of missed doses : If you miss a dose, take it within 12 hours; if it exceeds 12 hours, skip it and take the medicine on time next time.
3. Vomiting treatment : There is no need to take another dose after vomiting. Take the next dose according to the original plan.
1. First dose reduction of :240mg → 160mg (2 tablets of 80mg).
2. Secondary reduction of : 160mg → 80mg.
3. Serious adverse reactions : The drug needs to be suspended or permanently discontinued, such as recurrence of venous thromboembolism (VTE) or diagnosis of interstitial lung disease (ILD).
1. Diet : High-fat diet does not affect the efficacy of the medicine.
2. Skin care : Sun protection and alcohol-free moisturizing cream are required during and within 2 months after treatment.
3. Anticoagulation prevention : Preventive anticoagulation (such as low molecular weight heparin) is required 4 months before treatment, and vitamin K antagonists should be avoided.
1. Pregnant women : may cause fetal damage, so contraception is required until 3 weeks after the last dose.
2. Lactation : Breastfeeding is prohibited within 3 weeks after stopping the drug.
3. Hepatic and renal insufficiency : No dose adjustment is required for mild to moderate symptoms, and insufficient data for severe symptoms.
1. Common (≥20%) include: Rash, paronychia, infusion reaction (Amivantamab related ), myalgia, edema, etc.;
2. Serious adverse reactions include:VTE (36%), ILD (3.1%), severe rash (26%) and ocular toxicity (16%).
There are no clear contraindications, but there are specific warnings (such as embryotoxicity).
1. Strong/moderate CYP3A4 inducer (such as rifampicin) will significantly reduce the plasma concentration of lazertinib, so combined use should be avoided.
2. The dose of CYP3A4/BCRP substrate (such as midazolam, rosuvastatin) may need to be adjusted.
Store at room temperature 20°C-25°C, allow short-term exposure to 15°C-30°C.